5 Amendments of Christine SCHNEIDER related to 2020/2071(INI)
Amendment 308 #
Motion for a resolution
Paragraph 5
Paragraph 5
5. Calls on the Commission to address in its next pharmaceutical and industrial strategies issues relating to the availability and accessibility of medicines and manufacturers’ dependence on third countriesat the same time to ensure that the industry remains a world-leading innovator;
Amendment 322 #
Motion for a resolution
Paragraph 5 a (new)
Paragraph 5 a (new)
5a. Calls on the Commission to address the issue of the dependence of non-EU countries in the production of medicines, bearing in mind that the innovative industry already sources a large part of its active substances from Europe;
Amendment 383 #
Motion for a resolution
Paragraph 7
Paragraph 7
7. Notes that security of supply is an essential factor in combating shortages and must be used as a qualitative criterion in connection with the award of public pharmacy contracts and calls for tender for the supply of medicines, as recommended in Article 67 of Directive 2014/24/EU; proposes that investments in the manufacture of active ingredients and medicinal end products in the EU should also be a criterion;
Amendment 453 #
Motion for a resolution
Paragraph 11
Paragraph 11
11. Stresses the importance of research and innovation, and calls for the establishment of a genuine European network, given that the price of relocation must not be a deterioration in the quality of medical research, and emphasises that a stable research and development system can have a positive impact on production capacities and stability of supply; supports such an ecosystem based on stable intellectual property, targeted incentives for unmet medical needs, qualified scientific staff and robust public research institutes;
Amendment 629 #
Motion for a resolution
Paragraph 17 a (new)
Paragraph 17 a (new)
17a. Calls on the Commission to undertake a comprehensive study on the causes of supply shortages, taking particular account of the role of parallel trade in creating supply shortages which allows wholesalers to purchase medical products in one Member State and sell them in another;